Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.

See all 340 in Finance →

By

Leave a Reply

Your email address will not be published. Required fields are marked *